# Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
Canonical URL: https://biopharmsignal.com/news/APLS/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors
Ticker: APLS
Company: Apellis Pharmaceuticals
Source: Apellis Pharmaceuticals
Published: 2026-03-02 12:00 EST
Original Source URL: https://investors.apellis.com
## Summary

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and

## Article Body
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and
## Recent Company News
- 2026-03-31 10:59 EST — [Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology](https://biopharmsignal.com/news/APLS/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology) — Source: Apellis Pharmaceuticals
- 2026-03-02 12:00 EST — [Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors](https://biopharmsignal.com/news/APLS/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors) — Source: Apellis Pharmaceuticals
- 2026-02-24 12:05 EST — [Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Apellis Pharmaceuticals
- 2026-02-23 12:00 EST — [Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference) — Source: Apellis Pharmaceuticals
- 2026-02-19 12:00 EST — [Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting](https://biopharmsignal.com/news/APLS/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting) — Source: Apellis Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)